22/10/2019 10:08 pm Welcome to isteroids.com - BLOG

Wednesday 21, Apr 2010

  Protein may guard new blood vessels from leakage

Posted By
Pin it Share on Tumblr

Protein may guard new blood vessels from leakageA protein, known as angiopoietin-1 or Ang1, was recently found to increase growth of blood vessels now appears to guard the vessels from leakage as well, which can be seen as a potential boon in treating chronic inflammatory diseases and for new therapies that help in growth of healthy blood vessels in damaged heart and limbs.

It was disclosed that the protein may restore the leaky vessels to normal and blocks the effects of substances turning the vessels leaky besides complementing the action of another natural blood vessel growth stimulant known as VEGF (vascular endothelial growth factor).

The new findings, based on studies of blood vessels in the skin of mice, were reported by researchers at UC San Francisco and Regeneron Pharmaceuticals in the December 24 issue of Science.

Wednesday 16, Dec 2009

  Protein responsible for chronic rhinosinusitis with polyps tracked down

Posted By
Pin it Share on Tumblr

Protein responsible for chronic rhinosinusitis with polyps tracked downResearchers from the Johns Hopkins have suggested during a study that a protein, vascular endothelial growth factor, or VEGF, a protein important for normal blood vessel growth, is responsible for overgrowth of cells in development of polyps characterizing one of the most severe forms of sinusitis.

This finding by Johns Hopkins researchers is expected to give a new target for development of new therapies for treating this disease form, which usually resist all present forms of treatment.

The findings were published in the Dec. 1 American Journal of Respiratory and Critical Care Medicine and suggested that doctors can treat sinusitis in patients with polyps by making use of therapies that minimize VEGF in sinus tissues.

Tuesday 01, Dec 2009

  Novel therapy development for chronic sinusitis may be promoted by a new target

Posted By
Pin it Share on Tumblr

Novel therapy development for chronic sinusitis may be promoted by a new targetAccording to researchers at the Johns Hopkins, a protein that is known to stimulate growth of blood vessel is responsible for the cell overgrowth in polyps’ development signifying one of the most severe forms of sinusitis.

It is considered by many scientists that this result finding will be more than helpful when it comes to developing novel therapies to treat this disease form that typically resists all current treatments.

The findings suggest that medical practitioners could treat sinusitis in patients with polyps by making use of therapies that minimize VEGF (vascular endothelial growth factor) in sinus tissues.

 

 


Monday 19, Oct 2009

  Survival rate increased with Avastin in recurrent glioblastoma affected patients

Posted By
Pin it Share on Tumblr

Survival rate increased with Avastin in recurrent glioblastoma affected patientsAccording to a recent study that was conduced at 11 centers across the country and published in the early online version of the Journal of Clinical Oncology, survival rate gets increased with Avastin in recurrent glioblastoma affected patients. It was revealed during the study that the targeted therapy Avastin, alone or in combination with CPT-11 (chemotherapy drug) can considerably increase progression-free survival times and survival rates in patients with a deadly form of recurrent brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study said that positive results from Avastin have promoted the FDA to an accelerated approval of Avastin in May 2009 for use in patients with recurrent glioblastomas.

Avastin is an angiogenesis inhibitor that neutralizes VEGF (vascular endothelial growth factor), which is a chemical signal stimulating the growth of new blood vessels and has already been approved for use in metastatic colorectal, breast, and kidney cancers as well as non-small cell lung cancer.

Monday 27, Jul 2009

  Potential additional treatment for eye disease

Posted By
Pin it Share on Tumblr

Potential additional treatment for eye diseaseRecent studies conducted by pSivida Corporation, the manufacturer of Iluven, a miniaturized, injectable sustained drug delivery system showed that for the first time, Fluocinolone Acetonide (FA) acted as both a vascular endothelial growth factor (VEGF) inhibitor and as a neuroprotective. That means Fluocinolone Acetonide has properties that inhibit the growth of new blood vessels as well as the ability to protect the neurons from degeneration. These properties support expansion of FA use to other eye conditions such as age-related macular degeneration (AMD) both wet and dry.

AMD is a medical condition usually affecting older adults that result in loss of vision in the center due to damage to the retina. It is considered as the major source of blindness in the elderly aged fifty years and above.

Another condition which could greatly benefit from FA treatment is retinitis pigmentosa, a group of genetic eye conditions wherein symptoms include night blindness (nyctalopia) and reduction of the peripheral visual field (tunnel vision).

In the first study, Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial cells (ARPE – 19). VEGF inhibition is one method of treating wet AMD and is currently the most effective FDA-approved method of treatment for this disease.

In the second study, they found that chronic intravitreal infusion of FA preserves both retinal structure and function.

According to Yahoo finance:

BOSTON–(BUSINESS WIRE)–pSivida Corp. (NASDAQ:PSDV – News)(ASX:PVA – News), a leading drug delivery company, today announced that two newly-published peer reviewed scientific papers showed that Fluocinolone acetonide (FA) both inhibited VEGF production and protected retinal cells and function. These findings support expanding the treatment indications for the company’s lead product, Iluvien, a miniaturized, injectable, sustained-release drug delivery system that releases FA directly into the eye. Iluvien is licensed to Alimera Sciences, of Alpharetta, Georgia and is in Phase III clinical trials for the treatment of Diabetic Macular Edema. Initial data from the 950-patient trials are expected to be reported by the end of the year, with an NDA filing scheduled for early 2010.